Cell Therapies Begins Alzheimer's Treatment Production
The Australian CDMO is transferring technology to manufacture a novel cell therapy for future clinical trials.
Updated on Oct. 16, 2026 in Alzheimer’s
Live Poll
Do you believe medical research should prioritize treatments that replace lost function over slowing disease progression?
Cell Therapies has commenced the technology transfer of an Alzheimer's disease cell therapy candidate developed by S2N.Bio. The collaboration aims to establish manufacturing processes in Australia for a future human clinical trial.
Why it matters
This partnership seeks to strengthen Australia's sovereign manufacturing capabilities while advancing a novel approach to Alzheimer's treatment. By replacing lost neurons, the therapy offers a distinct strategy compared to current treatments that aim only to slow disease progression.
The therapy utilises unipotent, non-genetically modified neuroprecursor cells derived from a patient's own hair follicles to replace lost neurons. This process is currently being integrated into the Cell Therapies quality system.
The players
Cell Therapies
Cell Therapies is a commercial contract development and manufacturing organisation (CDMO) based in Australia.
S2N.Bio
S2N.Bio is a biotechnology company focused on developing innovative cell therapies.
SMART Cooperative Research Centre
The SMART Cooperative Research Centre is an Australian research initiative that facilitates collaboration between industry and academia.
The details
The technology transfer establishes analytical methods and documentation within the Australian facility to ensure compliance with good manufacturing practices (GMP). The treatment uses autologous cells, meaning the patient serves as their own donor, which avoids the complexities of genetic modification.
Timeline
GMP clinical production is scheduled for 2027 to support a first-in-human trial.
The Big Picture
This partnership operates under the umbrella of the SMART Cooperative Research Centre to facilitate Australian medical innovation. It reflects a broader trend of leveraging domestic research institutions to secure sovereign manufacturing pipelines for complex cell therapies.
Patients may eventually gain access to a unique regenerative treatment option that focuses on neuron replacement rather than traditional symptom management. As the technology moves toward a 2027 trial, it highlights the potential for future medical pathways that utilise a patient's own biological material.
The takeaway
This development represents a significant step toward localising advanced medical manufacturing in Australia. It highlights a shift toward using autologous, non-genetically modified cells in treating neurodegenerative conditions.
What happens next
GMP clinical production of trial materials is planned to commence in 2027.
Further reading
For more context on current research and clinical efforts, visit the Australia Alzheimer’s section.
Source note: This article includes information reported by Contract Pharma.
Live Poll
Do you believe medical research should prioritize treatments that replace lost function over slowing disease progression?
